Related Experiment Videos
Lithium and psychosis revisited
1Department of Psychiatry, Dallas Veterans Affairs Medical Center, TX 75216, USA.
Summary
A distinct subgroup of patients with lithium-responsive, nonaffective psychosis exists. These individuals show unique genetic, symptomatic, and biological differences, suggesting a separate disorder that may benefit from lithium treatment.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Psychoses are heterogeneous, complicating treatment.
- Differential medication response may delineate distinct psychotic subgroups.
- Lithium has shown efficacy in specific patient groups.
Purpose of the Study:
- To review evidence supporting a distinct subgroup of lithium-responsive, nonaffective psychosis.
- To explore the characteristics and potential distinctiveness of this subgroup.
- To identify areas for future research in lithium-responsive psychoses.
Main Methods:
- Literature review of studies on lithium response in nonaffective psychosis.
- Analysis of family history, prodromal adjustment, symptom presentation, and biological markers.
- Examination of challenge test results and preliminary etiological associations.
Main Results:
- A subgroup with lithium-responsive, nonaffective psychosis exhibits unique features.
- This subgroup shows less genetic loading, fewer negative symptoms, and distinct in vitro lithium ratios.
- Physostigmine challenge tests indicated greater symptom reduction, unlike apomorphine tests.
Conclusions:
- Evidence supports lithium-responsive nonaffective psychosis as a distinct entity.
- This subgroup may represent a phenocopy of other psychotic disorders.
- Further research is crucial to confirm its status and optimize treatment strategies.